ABOS: Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for ABOS
Across the 23 sessions after earlier ABOS headlines, the stock closed higher 13 times and lower 10 times, with a median move of 3.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ABOS | SPY |
|---|---|---|---|
| Oct 30, 2026 | Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint | -90.8% | -1.8% |
| Oct 26, 2026 | Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights | +14.6% | +0.7% |
| Oct 20, 2026 | Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 | +13.8% | +0.3% |
| Sep 11, 2026 | Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 | +2.1% | +0.9% |
| Sep 3, 2026 | Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences | -0.3% | +1.0% |
| Aug 12, 2026 | Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights | +1.6% | +0.3% |
Quantisnow market dataNASDAQ
ABOS
Acumen Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for ABOS
Full ABOS profile on Quantisnow Follow ABOS and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time